VISEN Pharmaceuticals

2561 · HKEX · China

Public Market Listing

2561HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for VISEN Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Growth hormone receptorProtein / enzyme therapeutic
Growth Hormone Deficiency
Approved
PTH1 receptor (PTH replacement)Peptide
Hypoparathyroidism

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
palopegteriparatide · YorvipathPhase 3Hypoparathyroidism
Est. primary completion 2027-08 · NCT07706764 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
lonapegsomatropin · SkytrofaPhase 3Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
Est. primary completion 2028-02 · NCT07221851 · CT.gov ↗
What to watch
September 2028 (1)
lonapegsomatropin · SkytrofaPhase 3Achondroplasia
Est. primary completion 2028-09 · NCT07924059 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.